Cholangiocarcinomas Completed Phase 2 Trials for Dasatinib (DB01254)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02428855Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic CholangiocarcinomaTreatment